Thyroid eye disease (TED) cannot be cured in the traditional sense, but it does burn itself out. The condition follows a predictable pattern: an active inflammatory phase lasting roughly one to three years, followed by a stable, inactive phase where the immune attack on the eye tissues stops. Most people with mild disease see it resolve on its own, either completely or partially. For those with moderate or severe TED, treatments can dramatically reduce inflammation, reverse eye bulging, and restore quality of life, but some degree of lasting change to the eyes or eye muscles persists in up to half of patients without intervention.
How TED Progresses on Its Own
TED follows what doctors call the Rundle curve, a pattern first described decades ago that still holds up. Inflammation ramps up quickly after onset, peaks somewhere between 13 and 24 months, and then gradually declines. The physical severity of the disease (how much the eyes bulge, how restricted the muscles become) peaks slightly later, around 19 to 24 months, then also improves. By about 36 months after symptoms first appear, the disease typically settles into its final inactive state.
This natural burnout is encouraging, but it comes with a catch. Once the inflammation fades, whatever tissue changes occurred during the active phase tend to stick around. Swollen muscles can become stiff and scarred. Fat deposits behind the eyes may not fully reabsorb. That means even though the disease “stops,” the cosmetic and functional effects don’t always disappear. This is why early treatment during the active window matters so much.
What “Inactive” Really Means
Doctors measure TED activity using a Clinical Activity Score, which tracks signs like pain, redness, and swelling. A score of 2 or below is generally considered inactive. Studies show that 45 to 65 percent of patients reach this threshold, meaning their disease has cooled down enough that the immune-driven inflammation is no longer doing damage. For mild cases, watchful monitoring and basic lifestyle changes are often enough, since the disease will remit completely or partially on its own in the majority of these patients.
Inactive disease is not the same as cured. Your eyes may still look different than they did before TED. You might still have some degree of bulging, eyelid retraction, or double vision. But the inflammatory process driving those changes has stopped, and that’s the point at which reconstructive options become available.
Treatments During the Active Phase
The goal during the active phase is to shut down inflammation as fast as possible, limiting the permanent damage left behind. The current first-line approach for moderate to severe TED is intravenous corticosteroids, given as a series of weekly infusions over about 12 weeks. This can be combined with orbital radiotherapy to further reduce inflammation and lower the total steroid dose needed.
The biggest shift in TED treatment came with teprotumumab (sold as Tepezza), the only therapy specifically approved for this condition. It works by blocking a receptor involved in the inflammatory process behind the eyes. In a phase 3 trial published in the New England Journal of Medicine, 83 percent of patients treated with teprotumumab saw at least 2 millimeters of reduction in eye bulging at 24 weeks, compared to just 10 percent on placebo. The average reduction was about 2.8 millimeters. Sixty-eight percent experienced meaningful improvement in double vision, and quality-of-life scores improved significantly. Treatment involves eight infusions given every three weeks.
For patients who don’t respond to steroids or teprotumumab, other biologic therapies are used off-label. A meta-analysis comparing the three main options found that tocilizumab (which targets an inflammatory signaling molecule) produced the largest drop in activity scores, about 3.5 points on the standard scale, slightly outperforming teprotumumab at 3.1 points. Rituximab, the third option, was safer overall but had more treatment failures. The choice between these depends on what’s driving each person’s disease and how they’ve responded to earlier treatments.
Surgery After the Disease Quiets Down
Reconstructive surgery is reserved for after TED becomes inactive and thyroid hormone levels have been stable. This is the phase where lasting damage gets addressed. The procedures follow a specific sequence: orbital decompression first (to reduce eye bulging), then eye muscle surgery (to correct double vision), and finally eyelid surgery.
Orbital decompression involves removing bone or fat from the eye socket to create more space. The amount of improvement depends on the surgical approach. Lateral wall decompression reduces eye bulging by an average of 4.2 millimeters, while more extensive procedures involving two and a half walls can achieve reductions of about 7.6 millimeters. These are significant improvements, often enough to restore a near-normal appearance. The tradeoffs include temporary numbness in about 29 percent of lateral decompressions and new double vision in about 9 percent, though more aggressive approaches carry higher complication rates.
Recurrence Is Possible
Even after TED goes inactive, it can come back. A study of 415 TED patients found a recurrence rate of 15.7 percent. Smoking is the single biggest modifiable risk factor. Patients who smoked during their first episode had a 22 percent recurrence rate, compared to 14.6 percent for nonsmokers. Smoking also makes active TED worse and reduces the effectiveness of treatment, so quitting is one of the most impactful things you can do at any stage of the disease.
Selenium and Mild Disease
For people with mild TED, selenium supplementation has shown genuine benefit. A randomized controlled trial found that selenium improved quality of life, reduced eye involvement, and slowed disease progression compared to placebo. The effect was specific to mild disease, and selenium is now commonly recommended as a low-risk supportive measure during the early stages. It won’t reverse moderate or severe TED, but for mild cases it may be enough to tip the balance toward a better outcome as the disease runs its natural course.
The Practical Bottom Line
TED is not a disease you cure once and forget about. It’s a disease that runs a course, and the outcome depends heavily on severity and timing. Mild cases often resolve with minimal or no treatment. Moderate to severe cases benefit enormously from aggressive treatment during the active window, especially within the first 24 months, followed by surgery if needed once things stabilize. The combination of modern biologics and reconstructive surgery means that most people with TED can get to a place where the disease no longer significantly affects their appearance, comfort, or vision, even if the underlying autoimmune tendency remains.